---
title: "Market Insight | GIANT BIOGENE surges over 4% again, outstanding performance of Singles' Day flagship products, CanSinoBIO's first day of pre-sale sees a 126% increase in GMV"
description: "Giant Biogene rose by over 4%, as of the time of publication, it rose by 4.05% to HKD 56.55, with a turnover of HKD 139 million. On the news front, according to Debon Securities, the sales of collagen"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/217698409.md"
published_at: "2024-10-24T02:46:06.000Z"
---

# Market Insight | GIANT BIOGENE surges over 4% again, outstanding performance of Singles' Day flagship products, CanSinoBIO's first day of pre-sale sees a 126% increase in GMV

> Giant Biogene rose by over 4%, as of the time of publication, it rose by 4.05% to HKD 56.55, with a turnover of HKD 139 million. On the news front, according to Debon Securities, the sales of collagen components were impressive at the end of the first phase of Double 11 in 2024. Based on data from Li Jiaqi's Tmall live broadcast room, Kemei's first-day presale GMV was approximately HKD 385 million, a year-on-year increase of 126%, accounting for 74% of the total Double 11 period, with growth rate and achievement rate both ranking first among domestic products. Among them, the collagen stick achieved sales of over 500,000 on the first day, with a GMV of HKD 315 million, making it the top-selling domestic product. China Merchants Securities pointed out that Giant Biogene's overall performance in the third quarter met expectations, approaching the guidance given for the second half of the year, and management expressed confidence in achieving the full-year guidance. In addition, this year's Double 11 event period has been extended overall, and preliminary data currently available also show the company's performance to be impressive, with the sales deposit situation of leading influencers meeting expectations

According to the Wise Finance APP, GIANT BIOGENE (02367) rose by over 4%, as of the time of publication, it increased by 4.05% to HKD 56.55, with a turnover of HKD 139 million.

On the news front, according to Debon Securities, the sales of collagen products were impressive after the first phase of Double 11 in 2024. Based on the data from Li Jiaqi's Tmall live broadcast room, the first day pre-sale GMV of KFM reached approximately HKD 385 million, a year-on-year increase of 126%, accounting for 23% of the total GMV for the entire Double 11 period, with both growth rate and achievement rate ranking first among domestic products. Among them, the collagen stick achieved sales of over 500,000 units on the first day, with a GMV of HKD 315 million, making it the top-selling domestic product.

China Merchants Securities pointed out that GIANT BIOGENE's overall performance in the third quarter met expectations and was close to the guidance given for the second half of the year. Management expressed confidence in achieving the full-year guidance. In addition, this year's Double 11 event period has been extended overall, and the preliminary data currently available also show a pleasing performance by the company, with the sales deposit situation of the leading influencers meeting expectations

### Related Stocks

- [02367.HK - GIANT BIOGENE](https://longbridge.com/en/quote/02367.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 早盤趨勢｜鉅子生物多頭信心鬆動，關鍵支撐岌岌可危？ | 1 月 27 日，鉅子生物（2367.HK）盤中弱勢震盪，盤面反覆探底，多次試探 28 元整數關口支撐未果。全天資金持續流出，綠盤成交佔比高，顯示多頭信心逐步鬆動，主力持倉籌碼開始鬆懈。 生物科技板塊過去一週受地方政策分歧影響，持續表現低迷 | [Link](https://longbridge.com/en/news/273815223.md) |
| 美團 (3690) 盈警，料去年度業績由盈轉虧 | 美團近日發出盈警，預計 2025 年度將錄得虧損 233 億至 243 億元人民幣，較 2024 年盈利 358 億元大幅惡化。虧損主要源於核心本地商業分部的經營虧損及對海外業務的加大投入。美團已加大對生態體系的投入以應對激烈競爭，包括強化 | [Link](https://longbridge.com/en/news/276027930.md) |
| 陶冬稱人民幣資產機會來了 科技自主牛市顯現 警示美債風險「黃金買貴不會買錯」 | 陶冬表示人民幣資產機會已來，科技自主牛市顯現，外資對中國資產前景看好。他指出當前應關注遠離央行控制的資產和科技突破。陶冬認為美聯儲將維持寬鬆政策，但短期內可能處於觀察期，且美債市場面臨風險，傳統的零風險資產邏輯已被顛覆。 | [Link](https://longbridge.com/en/news/276028904.md) |
| 陶冬：人民幣資產機會來了 科技自主牛市顯現 警示美債風險「黃金買貴不會買錯」 | 陶冬表示，人民幣資產機會已來，科技自主牛市顯現，當前是「資產為王」的時代，關注遠離央行控制的資產和科技突破。預計美聯儲將維持寬鬆政策，但短期內可能觀察。美債市場面臨風險，傳統零風險資產邏輯已被顛覆，需警惕未來利率可能降至 3% 左右。 | [Link](https://longbridge.com/en/news/276028666.md) |
| Mikrobiomik 獲得了用於治療艱難梭菌感染的腸道微生物羣療法的批准 | Mikrobiomik 已在西班牙獲得其口服療法 EUTEGRA (MBK-01) 的批准，用於治療艱難梭菌感染，標誌着其成為首個為此目的處理糞便微生物羣的組織。該療法採用 FSPIM 技術，為傳統抗生素治療提供了一種替代方案。此次批准是在 | [Link](https://longbridge.com/en/news/276345316.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.